# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-25-004635
Filing Date
2025-01-21
Accepted
2025-01-21 06:02:06
Documents
6
Period of Report
2025-02-06

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm252001-3_def14a.htm | DEF 14A | 899116
2 | GRAPHIC | lg_cyclacel-4c.jpg | GRAPHIC | 19400
3 | GRAPHIC | lg_secretarysoffistamp-bwlr.jpg | GRAPHIC | 13622
4 | GRAPHIC | px_cyclacel25pg01-4c.jpg | GRAPHIC | 299383
5 | GRAPHIC | px_cyclacel25pg02-4c.jpg | GRAPHIC | 226267
6 | GRAPHIC | sg_jeffreywbullock-bw.jpg | GRAPHIC | 10632
| Complete submission text file | 0001104659-25-004635.txt |  | 1653449

Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-50626 | Film No.: 25540242
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)